Home > News > Industry > Pharma News > Zydus Cadila gets DCGI...

Zydus Cadila gets DCGI nod for Phase 1 trial of novel molecule ZYIL1

By - Ruchika Sharma
Published On 2020-12-07 08:52 GMT   |   Update On 2020-12-07 08:52 GMT

New Delhi: Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'. In a regulatory filing, Zydus Cadila said "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral...

Login or Register to read the full article
Register Now

New Delhi: Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'.

In a regulatory filing, Zydus Cadila said "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process".

This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, Gastro-intestinal diseases (inflammatory bowel disease), renal diseases, and CNS diseases, the company added.
Pankaj R Patel, Chairman, Cadila Healthcare said: "We will study the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 in this phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need."
Last month, Zydus Cadila had filed the investigational new drug application for ZYIL1, positioned for management of critically ill Covid-19 patients. Shares of Cadila Healthcare were trading 1.85 percent higher at Rs 479.70 apiece on BSE.



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

USFDA Advisory Committee to convene meeting to discuss on Eli Lilly Alzheimer's drug donanemab
Lupin net profit surges 52 percent at Rs 359 crore in Q4
Surprise check at pharmacies: Noida admin seizes samples of three medicines
Gland Pharma bags USFDA nod for amyotrophic lateral sclerosis injection Edaravone
AstraZeneca says it will withdraw COVID-19 vaccine globally
Biological E Gets CDSCO Panel Nod for Continued Safety study of 14-valent pneumococcal polysaccharide conjugate vaccine
Issue of pharma pricing control in Australia raised by India
Dialysis chain NephroPlus raises Rs 850 crores in Series F round from Quadria Capital